GSK
@gsk.com
We discover, develop and deliver medicines and vaccines to create value for patients and shareholders.
Pinned
A child’s first steps. Dinner with old friends. What moments – big or small – matter to you? 🧡
Driven by our deep understanding of the root causes of disease, we’re accelerating our R&D in areas where we can make the most meaningful difference to patients.
🔗 gsk.to/3PPoNtO
Driven by our deep understanding of the root causes of disease, we’re accelerating our R&D in areas where we can make the most meaningful difference to patients.
🔗 gsk.to/3PPoNtO
#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4cJsjhu
Learn more: gsk.to/4cJsjhu
September 13, 2026 at 11:41 PM
#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4cJsjhu
Learn more: gsk.to/4cJsjhu
#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline.
Learn more: gsk.to/4xrKoZ1
Learn more: gsk.to/4xrKoZ1
September 13, 2026 at 12:32 AM
#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline.
Learn more: gsk.to/4xrKoZ1
Learn more: gsk.to/4xrKoZ1
#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/4xMvugV
Learn more: gsk.to/4xMvugV
September 10, 2026 at 6:05 AM
#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/4xMvugV
Learn more: gsk.to/4xMvugV
The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together.
#ERSCongress
#ERSCongress
September 9, 2026 at 9:33 AM
The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together.
#ERSCongress
#ERSCongress
We believe the future of respiratory care needs to be as diverse as the patients living with respiratory disease, supporting real-world use with longer-acting solutions that aim to offer greater choice and improve adherence.
September 5, 2026 at 9:30 AM
We believe the future of respiratory care needs to be as diverse as the patients living with respiratory disease, supporting real-world use with longer-acting solutions that aim to offer greater choice and improve adherence.
#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII.
Learn more: gsk.to/4iDDU5g
Learn more: gsk.to/4iDDU5g
September 1, 2026 at 6:03 AM
#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII.
Learn more: gsk.to/4iDDU5g
Learn more: gsk.to/4iDDU5g
#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB).
This approval reflects continued commitment to progress in liver disease research.
Learn more: gsk.to/45Goq9d
This approval reflects continued commitment to progress in liver disease research.
Learn more: gsk.to/45Goq9d
August 24, 2026 at 6:30 AM
#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB).
This approval reflects continued commitment to progress in liver disease research.
Learn more: gsk.to/45Goq9d
This approval reflects continued commitment to progress in liver disease research.
Learn more: gsk.to/45Goq9d
#News for #Investors and #Media: Today we announced that the US FDA accepted the application for one of our immuno-oncology therapies for priority review.
Learn more: gsk.to/3U5ph0D
Learn more: gsk.to/3U5ph0D
August 24, 2026 at 6:07 AM
#News for #Investors and #Media: Today we announced that the US FDA accepted the application for one of our immuno-oncology therapies for priority review.
Learn more: gsk.to/3U5ph0D
Learn more: gsk.to/3U5ph0D
Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus.
Learn more gsk.to/4be2p4M
Learn more gsk.to/4be2p4M
July 29, 2026 at 3:22 PM
Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus.
Learn more gsk.to/4be2p4M
Learn more gsk.to/4be2p4M
#News for #Investors and #Media:
At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare.
👉 Find out more: gsk.to/44YUip5
At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare.
👉 Find out more: gsk.to/44YUip5
July 29, 2026 at 2:19 PM
#News for #Investors and #Media:
At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare.
👉 Find out more: gsk.to/44YUip5
At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare.
👉 Find out more: gsk.to/44YUip5
Our global survey findings reveal ongoing misunderstandings about chronic hepatitis B (CHB), including gaps in awareness about prevention and its link to liver cancer.
On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai
On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai
July 28, 2026 at 2:30 PM
Our global survey findings reveal ongoing misunderstandings about chronic hepatitis B (CHB), including gaps in awareness about prevention and its link to liver cancer.
On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai
On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai
Today we’re announcing a £400 million investment in UK life sciences including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D
July 28, 2026 at 11:44 AM
Today we’re announcing a £400 million investment in UK life sciences including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: gsk.to/45qwVVv
#Q2Results $GSK
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: gsk.to/45qwVVv
#Q2Results $GSK
July 28, 2026 at 11:06 AM
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: gsk.to/45qwVVv
#Q2Results $GSK
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: gsk.to/45qwVVv
#Q2Results $GSK
#News for #investors and #media: Today our licensor Hansoh Pharma announced another positive pivotal dataset on an investigational antibody-drug conjugate in our oncology pipeline.
Learn more: gsk.to/45w7cLi
Learn more: gsk.to/45w7cLi
July 28, 2026 at 10:14 AM
#News for #investors and #media: Today our licensor Hansoh Pharma announced another positive pivotal dataset on an investigational antibody-drug conjugate in our oncology pipeline.
Learn more: gsk.to/45w7cLi
Learn more: gsk.to/45w7cLi
#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026.
Find out more in the press release gsk.to/44QBFUg
Find out more in the press release gsk.to/44QBFUg
July 27, 2026 at 5:05 PM
#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026.
Find out more in the press release gsk.to/44QBFUg
Find out more in the press release gsk.to/44QBFUg
#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one our therapies to treat ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4yButJ9
Learn more: gsk.to/4yButJ9
July 22, 2026 at 4:43 PM
#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one our therapies to treat ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4yButJ9
Learn more: gsk.to/4yButJ9
#News for #Investors and #Media: We’ll be at #AIDS2026 with ViiV Healthcare, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
👉 Find out more in the press release: gsk.to/4fdROcs
👉 Find out more in the press release: gsk.to/4fdROcs
July 21, 2026 at 8:08 AM
#News for #Investors and #Media: We’ll be at #AIDS2026 with ViiV Healthcare, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
👉 Find out more in the press release: gsk.to/4fdROcs
👉 Find out more in the press release: gsk.to/4fdROcs
#News for #Media and #Investors: Today we announced that the EMA has accepted our submission to update the label of one of our meningococcal vaccines. If approved, this could enable a 1-dose booster for certain individuals.
Learn more: gsk.to/4wf6det
Learn more: gsk.to/4wf6det
July 20, 2026 at 6:05 AM
#News for #Media and #Investors: Today we announced that the EMA has accepted our submission to update the label of one of our meningococcal vaccines. If approved, this could enable a 1-dose booster for certain individuals.
Learn more: gsk.to/4wf6det
Learn more: gsk.to/4wf6det
#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health.
Learn more: gsk.to/3T0EVd6
Learn more: gsk.to/3T0EVd6
July 16, 2026 at 2:25 PM
#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health.
Learn more: gsk.to/3T0EVd6
Learn more: gsk.to/3T0EVd6
#News for #investors and #media:
Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/44vsRTI
Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/44vsRTI
July 15, 2026 at 12:55 PM
#News for #investors and #media:
Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/44vsRTI
Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/44vsRTI
#News for #Media and #Investors: We’re excited to announce interim positive headline results from one of our clinical trial evaluating our immuno-oncology therapies.
More here: gsk.to/4w59dKg
More here: gsk.to/4w59dKg
July 13, 2026 at 6:05 AM
#News for #Media and #Investors: We’re excited to announce interim positive headline results from one of our clinical trial evaluating our immuno-oncology therapies.
More here: gsk.to/4w59dKg
More here: gsk.to/4w59dKg
#News for #Investors and #Media: Today, our licensor Hansoh Pharma announced pivotal data on an investigational antibody-drug conjugate in our oncology pipeline for the treatment cancers with high unmet needs.
Learn more: gsk.to/4vpmVGN
Learn more: gsk.to/4vpmVGN
July 10, 2026 at 11:05 AM
#News for #Investors and #Media: Today, our licensor Hansoh Pharma announced pivotal data on an investigational antibody-drug conjugate in our oncology pipeline for the treatment cancers with high unmet needs.
Learn more: gsk.to/4vpmVGN
Learn more: gsk.to/4vpmVGN
#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs).
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: gsk.to/44gOOFG
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: gsk.to/44gOOFG
June 17, 2026 at 3:12 PM
#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs).
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: gsk.to/44gOOFG
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: gsk.to/44gOOFG
Our new website, YourCancerOurChallenge.com, provides education and resources to support patients impacted by ovarian and endometrial cancers, myelofibrosis and multiple myeloma, from diagnosis and beyond.
Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl
Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl
June 12, 2026 at 1:00 PM
Our new website, YourCancerOurChallenge.com, provides education and resources to support patients impacted by ovarian and endometrial cancers, myelofibrosis and multiple myeloma, from diagnosis and beyond.
Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl
Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl
#News for #Investors and #Media: Today we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: gsk.to/444M6Da
Learn more: gsk.to/444M6Da
June 12, 2026 at 6:08 AM
#News for #Investors and #Media: Today we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: gsk.to/444M6Da
Learn more: gsk.to/444M6Da